



## Guidelines on autopsy practice: Fetal autopsy (2<sup>nd</sup> trimester fetal loss and termination of pregnancy for congenital anomaly)

June 2017

**Series authors:** Dr Michael Osborn, Imperial College Healthcare NHS Trust  
Professor Jim Lowe, Nottingham University Hospitals NHS Trust

**Specialist authors:** Dr Phillip Cox, Birmingham Women's Hospital NHS Foundation Trust  
Dr Beata Hargitai, Birmingham Women's Hospital NHS Foundation Trust  
Dr Tamas Marton, Birmingham Women's Hospital NHS Foundation Trust

Unique document number	G161
Document name	Guidelines on autopsy practice: Fetal autopsy (2 <sup>nd</sup> trimester fetal loss and termination of pregnancy for congenital anomaly)
Version number	1
Produced by	The specialist content of this guideline has been produced by Dr Phillip Cox MBBS, FRCPath, PhD, Consultant Perinatal Pathologist; Dr Beata Hargitai, MD, Affiliate Member of RCPATH, PhD, Consultant Perinatal Pathologist; Dr Tamas Marton MD, FRCPath, PhD, Consultant Perinatal Pathologist, all at the Birmingham Women's Hospital.
Date active	15 June 2017
Date for review	15 June 2022
Comments	In accordance with the College's pre-publication policy, this document was on The Royal College of Pathologists' website for consultation from 13 March to 10 April 2017. All other comments regarding this document should be sent to the College's non-forensic autopsy pathology lead, via <a href="mailto:clinicaleffectiveness@rcpath.org">clinicaleffectiveness@rcpath.org</a> . This document will replace earlier editions and is part of the Guidelines on autopsy practice series. <b>Dr Lorna Williamson</b> <b>Director of Publishing and Engagement</b>

The Royal College of Pathologists  
4th Floor, 21 Prescot Street, London. E1 8BB  
Tel: 020 7451 6700  
Web: [www.rcpath.org](http://www.rcpath.org)

Registered charity in England and Wales, no. 261035  
© 2017, The Royal College of Pathologists

This work is copyright. You may download, display, print and reproduce this document for your personal, non-commercial use. Requests and inquiries concerning reproduction and rights should be addressed to The Royal College of Pathologists at the above address. First published: 2017



## Contents

Foreword .....	3
1 Introduction.....	4
2 The role of the autopsy .....	5
3 Pathology of encountered at autopsy.....	5
4 Specific health and safety aspects.....	5
5 Consent.....	6
6 Clinical information relevant to the autopsy.....	6
7 The autopsy procedure .....	6
8 Limited autopsy.....	8
9 Specific organ systems to be considered.....	8
10 Organ retention.....	8
11 Histological examination .....	8
12 Toxicology .....	9
13 Other relevant samples (as indicated by history and macroscopic findings).....	9
14 Imaging.....	10
15 Autopsy report .....	10
16 Criteria for audit .....	11
17 References .....	12
Appendix A Structured autopsy request form.....	14
Appendix B Summary table . Explanation of grades of evidence.....	16
Appendix C AGREE compliance monitoring sheet .....	17



NICE has accredited the process used by The Royal College of Pathologists to produce its clinical guidelines. Accreditation is valid until July 2022. More information on accreditation can be viewed at [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

## Foreword

The autopsy guidelines published by The Royal College of Pathologists (RCPath) are guidelines that enable pathologists to deal with non-forensic consent and Coroners' post-mortem examinations in a consistent manner and to a high standard. They are written for the profession; some technical detail may be distressing to a lay audience.

The guidelines are systematically developed statements to assist the decisions of practitioners and are based on the best available evidence at the time the document was prepared. Given that much autopsy work is single observer and cannot realistically be repeated, it has to be recognised that there is no reviewable standard that is mandated beyond that of the FRCPATH Part 2 examination. Nevertheless, much of this can be reviewed against ante-mortem imaging and other data. It may be necessary or even desirable to depart from the guidelines in the interests of specific patients and special circumstances. The medico-legal risk of departing from the guidelines should be assessed by the autopsy pathologist; just as adherence to the guidelines may not constitute defence against a claim of negligence, so a decision to deviate from them should not necessarily be deemed negligent.

There is a general requirement from the General Medical Council to have continuing professional development (CPD) in all practice areas and this will naturally encompass autopsy practice. Those wishing to develop expertise/specialise in pathology are encouraged to seek appropriate educational opportunities and participate in the relevant EQA scheme.

The guidelines themselves constitute the tools for implementation and dissemination of good practice.

The stakeholders consulted for this document were:

- British and Irish Paediatric Pathology Association (BRIPPA)
- Stillbirth and Neonatal Death Charity (SANDS)
- The Royal College of Obstetricians and Gynaecologists (RCOG)
- Antenatal Results and Choices (ARC)
- Miscarriage Association
- Human Tissue Authority (HTA) and its Histopathology Working Group, which includes representatives from the Association of Anatomical Pathology Technology, Institute of Biomedical Science, The Coroners Society of England and Wales, the Home Office Forensic Science Regulation Unit and Forensic Pathology Unit and the British Medical Association.

The information used to develop this document was derived from current medical literature and a previous version of this guideline. As far as possible, this guideline is based on published evidence, but where this does not exist it represents custom and practice, and is based on the substantial clinical experience of the authors and colleagues. All evidence included in this guideline has been graded using modified SIGN guidance. see Appendix B.

No major organisational changes or cost implications have been identified that would hinder the implementation of the guidelines.

A formal revision cycle for all guidelines takes place on a five-year cycle. The College will ask the authors of the guideline, to consider whether or not the guideline needs to be revised. A full consultation process will be undertaken if major revisions are required. If minor revisions or changes are required a short note of the proposed changes will be placed on the College website for two weeks for members' attention. If members do not object to the changes, the short notice of change will be incorporated into the guideline and the full revised version (incorporating the changes) will replace the existing version on the College website.

The guideline has been reviewed by the College's Clinical Effectiveness Department, Death Investigations Group, Lay Governance Group and Publications Department and was placed on the College website for consultation with the membership from 13 March to 10 April 2017. All comments received from the membership were addressed by the author to the satisfaction of the Director of Publishing and Engagement.

This guideline was developed without external funding to the writing group. The College requires the authors of guidelines to provide a list of potential conflicts of interest; these are monitored by the Clinical Effectiveness Department and are available on request. The authors of this document have declared that there are no conflicts of interest.

## 1 Introduction

Post-mortem examination of a baby following spontaneous or missed miscarriage in the second trimester (11<sup>+0</sup>. 23<sup>+6</sup> weeks gestation) may provide a complete or partial explanation of the pregnancy loss, whilst following termination of pregnancy for fetal abnormality a post-mortem examination may provide a specific diagnosis. In all situations post-mortem may provide information relevant to the management of subsequent pregnancies.<sup>1-4</sup> Autopsy is the single most useful investigation and provides information that changes or significantly adds to the clinical diagnosis in nearly half of cases.<sup>5,6</sup> The autopsy is also a valuable audit of clinical care and may facilitate learning from adverse events.

This guideline has been created to assist the pathologist undertaking autopsies in cases of second trimester (late) miscarriage, second trimester intrauterine death (missed miscarriage) and termination of pregnancy for fetal abnormality. It provides practical technical advice on performing the autopsy, guidance on the use of additional investigations and minimum standards for the content of the autopsy report. It is intended as a guide to reasonable practice, rather than a policy statement. If followed, the output from the autopsy should be sufficient to provide useful feedback to the family, to the clinicians involved in the case and for local and national audit. Where possible, references are provided, but it is inevitable that many of the suggestions are based on common UK practice rather than on published evidence, as the latter is often non-existent or sparse. Many pathologists have adopted approaches based on their own experience, evidence and resources, which may differ from these guidelines but achieve the same outcome. This document does not aim to change such approaches. In addition, the document is not intended as a replacement for standard textbooks, but highlights the principles of undertaking and reporting perinatal autopsies. For detailed guidance on undertaking the autopsy in specific circumstances, the reader is referred to the Further reading list below.

In England, Wales and Northern Ireland, autopsy facilities and procedures must be covered by appropriate licences issued by the HTA and consent procedures must be compliant with the relevant HTA *Code of Practice*.<sup>7</sup> Separate legislation applies in Scotland, which does not impose a system of licensing.

As with other complicated autopsy scenarios such as maternal deaths, it is preferable that all fetal autopsies are performed by a perinatal/paediatric pathologist or a general histopathologist with an interest and suitable expertise in such matters.

### 1.1 Target users of this guideline

The target primary users of this guideline are UK consultant and trainee perinatal/paediatric pathologists and general histopathologists with an interest in perinatal pathology. The recommendations will also be of value to pathologists working outside the UK, obstetricians, neonatal paediatricians and bereavement midwives.

## **2 The role of the autopsy**

The role of the autopsy is to:

- provide information regarding the baby to the bereaved family
  - . establish the immediate cause of second trimester miscarriage or factors that may have contributed to the pregnancy loss
  - . identify the immediate cause of second trimester intrauterine death (missed miscarriage)
  - . identify concomitant diseases, particularly those with implications for subsequent pregnancies (e.g. growth restriction, malformation, maternal diabetes)
  - . identify evidence of genetic disease and to allow determination of the likely recurrence risk
- provide pathology input for local perinatal mortality, fetal medicine or clinical genetics review meetings
- provide information for audit purposes (e.g. antenatal diagnosis, pregnancy and intrapartum care)
- provide information for national clinical outcome review programmes and local or national congenital malformation registers.

## **3 Pathology encountered at autopsy**

- Amniotic infection sequence
- Oligohydramnios
- Growth restriction: symmetric, asymmetric (nutritional)
- Viral/protozoal infection (CMV, Parvovirus, toxoplasmosis, other)
- Congenital malformation (all systems)
- Hydrops fetalis
- Fetal akinesia sequence
- Placental and umbilical cord disease
- Changes in the baby and placenta secondary to intrauterine death.

The above is not an exhaustive list and users are referred to the relevant textbooks.

## **4 Specific health and safety aspects**

The pathologist needs to know the results of the antenatal infection screens.

In regions of high maternal HIV prevalence, autopsy practice using universal precautions will significantly protect against accidental transmission.

## 5 Consent

- Regardless of the gestation, post-mortem examination may only be performed if informed consent has been given, typically by the mother or both of the parents. Fetal tissue is considered in law to be the mother's tissue, and therefore tissue from the living.
- The consent process should be compliant with the requirements of the HTA's *Code of Practice: Code A: Guiding Principles and the Fundamental Principle of Consent*.<sup>7</sup>
- The autopsy consent form should be compliant with the model consent form for perinatal post mortem developed by SANDS, the stillbirth and neonatal death charity, in consultation with the HTA.<sup>8</sup>
- The pathologist performing the autopsy must see the completed consent form, either as a physical copy or electronically, before commencing the autopsy. Any limitations on the scope of the autopsy must be complied with.
- Any concerns regarding the validity of the consent should be resolved before commencing the autopsy.

*[Level of evidence: D]*

## 6 Clinical information relevant to the autopsy

(Best obtained using structured request form, see Appendix A.)

- Patient identification details.
- Maternal age/date of birth.
- Maternal height, weight and BMI.
- Relevant medical and family history, including consanguinity.
- Obstetric history, previous pregnancies/deliveries, including previous fetal and neonatal losses (and if post-mortem examination had been carried out), malformation and growth restriction and other complications.
- History of current pregnancy, including:
  - estimated delivery date
  - antenatal infection screen, including HIV
  - abnormal findings from ultrasound or other antenatal investigations (copies of reports are helpful)
  - hypertension/bleeding/pyrexia/membrane rupture
  - events leading up to delivery
  - for late miscarriages, live born or stillborn.

*[Level of evidence: GPP]*

## 7 The autopsy procedure<sup>9</sup>

- Requires availability of appropriately sized instruments for small and very small fetuses; balances for weighing babies and organs (to at least nearest 0.1 g); charts of normal values (baby weight and measurements, organ weights and placenta weight)

- Whole body X-ray for gestational assessment, malformation, etc. Recommended in all cases; mandatory for suspected skeletal dysplasia. Other imaging modalities may be appropriate in some circumstances and if available.
- Photography recommended in all cases, essential to document external and internal abnormalities. Digital photography and secure storage preferred.
- Routine external body measurements (body weight, crown-rump length, crown-heel length, foot length, occipito-frontal circumference)
- Detailed external examination, including: muscle bulk, maceration, local/generalised oedema, pallor, dysmorphic features, assessment of patency of orifices (including choanae) and palatal fusion, limbs, hands and feet and genitalia
- T- or Y-shaped skin incision on body
- Central nervous system (CNS) examination:
  - . median posterior or transverse posterior parietal scalp incision
  - . observation of maturity to assist gestational assessment
  - . consider removal under water
  - . if suspected CNS malformation (including ventriculomegaly), examination of posterior fossa structures by posterior approach.
  - . Consider referring the whole central nervous system for neuropathological examination in appropriate cases. This may include sampling peripheral nervous tissue (nerve root, peripheral nerve, muscle etc). Consulting the neuropathology team may be helpful if there is doubt about sampling.
- Detailed systematic examination of other internal organs, including:
  - . umbilical arteries and vein, ductus venosus
  - . *in situ* examination of the heart and great vessels with sequential segmental analysis of malformations
  - . *in situ* examination of thoracic and abdominal organs; consider removing in continuity to assess abnormal structures crossing diaphragm
  - . weights of internal organs (minimum: brain, heart, lungs, liver, kidneys, thymus, adrenals, spleen)
  - . apply special dissection techniques where appropriate.
- Detailed examination of placenta and umbilical cord, including:
  - . trimmed weight (after extraplacental membranes and cord detached)
  - . dimensions of placenta (width in two planes and thickness)
  - . umbilical cord: length, diameter, insertion into placental disc, number of vessels, coiling, lesions
  - . membranes: appearance
  - . fetal surface/chorionic vessels: appearance, infection
  - . maternal surface: completeness, craters
  - . slicing at approximately 1 cm intervals to evaluate parenchyma for colour and focal abnormalities.

*[Level of evidence: GPP]*

## 8 Limited autopsy

Where consent for a full autopsy is not given, limited examination may be of value.<sup>10</sup>

Forms of limited examination include:

- autopsy limited to one or more body cavities
- open or needle biopsy of specific internal organs (if feasible)
- external examination of the body with X-ray, photography and genetics (if indicated)
- placental examination only (with genetic testing if indicated)<sup>11</sup>
- imaging (CT, MRI . if available) alone or with targeted biopsies.<sup>12</sup>

*[Level of evidence: C]*

## 9 Specific significant organ systems

None. All are of significance.

## 10 Organ retention

- Short-term retention of organs to allow fixation does not require specific consent, provided they are reunited with the body before release for burial/cremation.
- Specific consent should be sought for long-term retention beyond the release of the body, for the purpose of examining the organs. Consider for extra-cranial organs with congenital malformations (particularly heart) if input not available from a perinatal pathologist or cardiac morphologist on site at the time of examination, and the abnormality cannot be satisfactorily recorded by photography.
- Brain for macroscopic and histological assessment. In practice, submersion for a minimum of 2. 3 days in 20% formalin ( $\pm 5\%$  acetic acid) will usually produce sufficient fixation to allow adequate sectioning and block sampling to allow the brain to be returned to the body before release for funeral. If there is doubt consult the local neuropathology team.

*[Level of evidence: GPP]*

## 11 Histological examination

Recommended blocks required at full autopsy:<sup>9</sup>

- thymus
- heart (septum and free walls)
- lungs (right and left . each lobe)
- liver (both major lobes)
- pancreas
- spleen
- adrenal glands

- kidneys
- muscle and diaphragm
- stomach, small and large bowels
- larynx/trachea and thyroid
- bone: rib including growth plate in stillbirth; long bone (including growth plate), vertebral body and skull mandatory for suspected skeletal dysplasia
- brain: if preservation allows include cerebral cortex and periventricular white matter (frontal, parietal, temporal and occipital), deep grey matter (caudate, striatum, thalamus), hippocampus, midbrain (inferior colliculi), pons, medulla (inferior olives), cerebellum with dentate nucleus. Sampling may by necessity be more restricted if there is advanced autolysis
- other organ lesions as appropriate
- placenta (at least three full-thickness blocks, plus focal lesions)
- membrane roll
- umbilical cord (at least two).

*[Level of evidence: D]*

A record of the samples taken should be kept and tissue blocks and slides should be traceable within the laboratory, in line with the requirements of HTA and the UK Accreditation Service.

## **12 Toxicology**

None required.

## **13 Other samples (as indicated by history and macroscopic findings)**

- Bacteriology (may be helpful when there is amniotic infection):
  - . lung (swab/tissue)
  - . blood (swab/formal culture)
  - . other, as dictated by clinical history or macroscopic findings.
- Genetics:
  - . skin/muscle/cardiac blood
  - . placenta
  - . other samples as recommended by local genetics department
  - . consider retention of frozen tissue sample (liver/lung/other) as further DNA resource.
- Virology
  - . Samples as indicated by clinical history or macroscopic findings.
- Biochemistry, electron microscopy
  - . Consider in cases of fetal akinesia and hydrops fetalis, if tissue preservation allows.

- Fibroblast culture and/or snap frozen liver/muscle for metabolic biochemistry if indicated.

*[Level of evidence: D]<sup>1-4</sup>*

## **14 Imaging**

Imaging-based post-mortem examination should never be undertaken without an expert external examination of the body having first been performed by an appropriately trained and experienced individual. Imaging modalities, in addition to X-ray, which may be of value include MRI<sup>12</sup> and micro-CT<sup>13</sup>.

The role of MRI imaging in perinatal autopsies has been investigated.<sup>12</sup> MRI imaging can give useful information, particularly on structural malformations; however, it is poor in detecting infection and in cases of significant maceration. Targeted biopsies may also be considered, but both MRI imaging and the equipment and skills needed to take endoscopic biopsies at post-mortem examination are currently not widely available.

*[Level of evidence: C]*

## **15 Autopsy report**

If resources allow, units may choose to issue a provisional report giving details of the macroscopic findings, shortly after the examination of the body, followed by a final report when all histology and other tests have been completed. Alternatively, only a single final report may be produced.

The report should include the following sections:<sup>9</sup>

- demographic and identification data
- details of autopsy consent and limitations
- body weight and appropriateness for gestation
- body measurements
- list of main findings
- clinicopathological summary (final report)
- summary of clinical history
- systematic description of external and internal findings and placental examination
- organ weights with relevant reference values and ratios
- details of ancillary tests taken (and results . final report)
- histology (final report)
- list of histology tissue blocks (final report).

*[Level of evidence: GPP]*

### **15.1 Clinicopathological summary**

The summary should include:

- an assessment of gestational age at death

- in second trimester intrauterine death, the degree of maceration and likely timing and cause of death (if determined)
- in miscarriage, the likely cause of the miscarriage
- as appropriate, explicit statements regarding the presence/absence of growth restriction, malformation and infection (negative findings are helpful and may be crucial)
- for termination of pregnancy, concordance or discordance of findings with the clinical history and prenatal testing, likely/possible unifying diagnosis and recommendation for genetic referral or further tests if appropriate
- identification of those cases with an increased risk of recurrence (including genetic disease, growth restriction, placental pathology) and requirement/possibility of additional testing.

## 16 Criteria for audit

The following standards are suggested criteria that might be used in periodic reviews to ensure a post-mortem examination report meets national standards

- Supporting documentation:
  - . standards: supporting documentation was submitted with the body in 95% of cases. (NB it is recommended that an autopsy should not be commenced in the absence of clinical information)
  - . standards: 95% of submitted information is satisfactory, good or excellent
  - . standards: a correctly completed autopsy consent form, meeting national requirements is submitted with 95% of cases. (NB an autopsy must not be commenced unless the pathologist has seen a physical copy of the consent form and it is correctly completed).
- Autopsy report:
  - . standards: 100% of autopsy reports must include all of the sections detailed in section 15 (above)
  - . standards: in 100% of autopsy reports the information documented is satisfactory, good or excellent
  - . standards: in 100% of autopsy reports the clinicopathological summary is clear and concise and when appropriate, contains the information detailed above.

## 17 References

1. Meier PR, Manchester DK, Shikes RH, Clewell WH, Stewart M. Perinatal autopsy: its clinical value. *Obstet Gynecol* 1986;67:349. 351.
2. Porter HJ, Keeling JW. Value of perinatal necropsy examination. *J Clin Pathol* 1987;40: 180. 184.
3. Faye-Petersen OM, Guinn DA, Wenstrom KD. Value of perinatal autopsy. *Obstet Gynecol* 1999;94:915. 920.
4. Gordijn SJ, Erwich JJ, Khong TY. Value of the Perinatal Autopsy: Critique. *Pediatric and Developmental Pathology* 2002;5:480. 488.
5. Johns N, Al-Salti W, Cox P, Kilby MD. A comparative study of prenatal ultrasound findings and post-mortem examination in a tertiary referral centre. *Prenat Diagn* 2004;24:339. 346.
6. Saller DN Jr, Lesser KB, Harrel U, Rogers BB, Oyer CE. The clinical utility of the perinatal autopsy. *JAMA* 1995;273:663. 665.
7. Human Tissue Authority. *Codes of Practise*. Accessed December 2016. Available at: [www.hta.gov.uk/guidance-professionals/codes-practice](http://www.hta.gov.uk/guidance-professionals/codes-practice)
8. The Stillbirth and Neonatal Death Charity. *The Sands perinatal post mortem consent package* [www.hta.gov.uk/policies/sands-perinatal-post-mortem-consent-package](http://www.hta.gov.uk/policies/sands-perinatal-post-mortem-consent-package) (accessed December 2016)
9. The Royal College of Obstetricians and Gynaecologists and Royal College of Pathologists. *Fetal and Perinatal Pathology: Report of a Joint Working Party*. London: RCOG Press, 2001.
10. Wright C, Lee RE. Investigating perinatal death: a review of the options when autopsy consent is refused. *Arch Dis Child Fetal Neonatal Ed* 2004;89:285. 288.
11. Heazell AE, Martindale EA. Can post-mortem examination of the placenta help determine the cause of stillbirth? *J Obstet Gynaecol* 2009;29:225. 228.
12. Thayyil S, Sebire NJ, Chitty LS, Wade A, Chong W, Olsen O *et al*. Post-mortem MRI versus conventional autopsy in fetuses and children: a prospective validation study. *Lancet* 2013;382:223. 233.
13. Lombardi CM, Zambelli V, Botta G, Moltrasio F, Cattoretti G, Lucchini V *et al*. Postmortem microcomputed tomography (micro-CT) of small fetuses and hearts. *Ultrasound Obstet Gynecol* 2014;44:600. 609.

## Further reading

1. Wigglesworth JS, Singer DB (eds). *Textbook of Fetal and Perinatal Pathology, Volume 2 (2<sup>nd</sup> edition)*. Malden: Blackwell Science, 1998.
2. Khong TY. The perinatal necropsy. In: Khong TY, Malcomson RDG (eds). *Keeling's Fetal and Neonatal Pathology (5<sup>th</sup> edition)*. London: Springer, 2015.
3. Bove KE. Practice guidelines for autopsy pathology . the perinatal and pediatric autopsy. *Arch Pathol Lab Med* 1997;121:368. 376.

4. Gilbert-Barness E, Kapur R, Oligny LL, Siebert J (eds.). *Potter's Pathology of the Fetus, Infant and Child (2<sup>nd</sup> edition)*. Philadelphia: Mosby Elsevier, 2007.
5. Baergen RN. *Manual of Pathology of the Human Placenta (2<sup>nd</sup> edition)*. New York: Springer, 2011.

**Appendix A Specimen autopsy request form**

**Clinical information for fetal/perinatal post-mortem examination**

Please attach **mother's** sticker here  
 Family name .....  
 First name .....  
 DOB / /  
 Reg no.....  
 Consultant .....

Please attach **baby's** sticker here  
 Family name .....  
 First name .....  
 DOB / /  
 Reg no .....  
 Consultant .....

Ethnic origin \_\_\_\_\_ Father's ethnic origin (if known) \_\_\_\_\_ Baby's sex: M/F  
 Referring hospital \_\_\_\_\_ Ward \_\_\_\_\_  
 Hospital of birth (if different) \_\_\_\_\_

**RELEVANT HISTORY:**

Maternal height: \_\_\_\_\_ cm  
 Booking weight: \_\_\_\_\_ kg  
 Consanguinity Y/N

**Previous pregnancies: G \_\_\_\_\_ P: \_\_\_\_\_**

Date	Gestation	Delivery	Sex	Outcome
1. _____				
2. _____				
3. _____				
4. _____				
5. _____				

**THIS PREGNANCY:** booked / unbooked LMP \_\_\_\_\_ EDD \_\_\_\_\_ BMI \_\_\_\_\_

Gestation: by dates: \_\_\_\_\_/40 by scan : \_\_\_\_\_/40 weeks Blood group : \_\_\_\_\_, Rh D pos / neg

HBsAg pos / neg Red cell antibodies \_\_\_\_\_

Trisomy screening results \_\_\_\_\_ Medications \_\_\_\_\_

Abnormal USS findings \_\_\_\_\_

Antenatal diagnostic procedures / results: \_\_\_\_\_

\_\_\_\_\_ Karyotype: \_\_\_\_\_

Threatened abortion: no / yes When _____	Severe anaemia: no / yes
Antepartum haemorrhage: no / yes When _____	Infection risk: low / high Reason _____
Hypertension: no/yes max b.p. _____	Maternal pyrexia: no / yes When _____
Pre-eclampsia: no/ yes when _____	Other problem _____

**LABOUR:** onset: spont. / medical/ none IOL for: IUD / TOP / other \_\_\_\_\_ Fetocide: y / n date \_\_\_\_\_

Presentation: vertex / breech / other \_\_\_\_\_ Liquor volume: normal / reduced / increased; colour \_\_\_\_\_

Rupture of membranes: date \_\_\_\_\_ time \_\_\_\_\_ Augmentation (Syntocinon): yes / no

1st stage: \_\_h \_\_min 2<sup>nd</sup> stage: \_\_h \_\_min Fetal heart last heard (S/B): date \_\_\_\_\_ time \_\_\_\_\_

Fetal distress: yes / no specify \_\_\_\_\_

**Delivery:** spontaneous / assisted (forceps/ventouse) / CS (elective/emergency) date \_\_\_\_\_ time \_\_\_\_\_

**Death:** date \_\_\_\_\_ time \_\_\_\_\_

**Baby:** Birth weight \_\_\_\_\_g Apgars: 1<sup>st</sup> min \_\_\_\_\_ 5<sup>th</sup> min \_\_\_\_\_ 10<sup>th</sup> min \_\_\_\_\_

**ABNORMALITIES NOTED:** nil / \_\_\_\_\_

**For live born infants:**

RESUSCITATION: nil / mucus extraction / oxygen / mask / intubation / other \_\_\_\_\_

Surfactant: yes / no

**NEONATAL PROBLEMS:**

1. \_\_\_\_\_
2. \_\_\_\_\_
3. \_\_\_\_\_
4. \_\_\_\_\_
5. \_\_\_\_\_

**PROCEDURES:**

1. \_\_\_\_\_
2. \_\_\_\_\_
3. \_\_\_\_\_
4. \_\_\_\_\_
5. \_\_\_\_\_

**BRIEF SUMMARY OF LATER SYMPTOMS / TREATMENTS AND MAJOR INVESTIGATIONS** (including CPAP/ventilation, IV therapy, fits, episodes of collapse, pneumonia, pneumothorax, bleeding problems, type of feeding etc.; If complex course, please send photocopy of relevant pages of notes):

**SUSPECTED CAUSE(S) OF DEATH:**

**DEATH REGISTERED AS:** livebirth / stillbirth / not registered (miscarriage)

**BRIEF SUMMARY OF MAIN HISTORY / SPECIAL POINTS TO BE NOTED AT POST-MORTEM:**

Referring doctor / midwife: \_\_\_\_\_ Contact no. / bleep no. \_\_\_\_\_

**ALL BABIES AND PLACENTAS SHOULD BE SENT FRESH IN LEAKPROOF, OPAQUE CONTAINERS  
UNLESS THERE IS AN INFECTIOUS HAZARD**

(In this case, phone to discuss whether the specimen should be fixed in 10% formalin before transportation)

It is essential to send the placenta with a fetus / infant.

**ALL SPECIMENS MUST BE CLEARLY LABELLED AND ACCOMPANIED WITH A COMPLETED  
REQUEST AND CONSENT FORM**

## Appendix B Summary table – Explanation of grades of evidence

(modified from Palmer K *et al. BMJ* 2008;337:1832)

Grade (level) of evidence	Nature of evidence
Grade A	<p>At least one high-quality meta-analysis, systematic review of randomised controlled trials or a randomised controlled trial with a very low risk of bias and directly attributable to the target population</p> <p>or</p> <p>A body of evidence demonstrating consistency of results and comprising mainly well-conducted meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a low risk of bias, directly applicable to the target population.</p>
Grade B	<p>A body of evidence demonstrating consistency of results and comprising mainly high-quality systematic reviews of case-control or cohort studies and high-quality case-control or cohort studies with a very low risk of confounding or bias and a high probability that the relation is causal and which are directly applicable to the target population</p> <p>or</p> <p>Extrapolation evidence from studies described in A.</p>
Grade C	<p>A body of evidence demonstrating consistency of results and including well-conducted case-control or cohort studies and high-quality case-control or cohort studies with a low risk of confounding or bias and a moderate probability that the relation is causal and which are directly applicable to the target population</p> <p>or</p> <p>Extrapolation evidence from studies described in B.</p>
Grade D	<p>Non-analytic studies such as case reports, case series or expert opinion</p> <p>or</p> <p>Extrapolation evidence from studies described in C.</p>
Good practice point (GPP)	<p>Recommended best practice based on the clinical experience of the authors of the writing group</p>

## Appendix C      AGREE II compliance monitoring sheet

The guidelines of The Royal College of Pathologists comply with the AGREE II standards for good quality clinical guidelines. The sections of this guideline that indicate compliance with each of the AGREE II standards are indicated in the table below.

<b>AGREE II standard</b>	<b>Section of guideline</b>
<b>Scope and purpose</b>	
1 The overall objective(s) of the guideline is (are) specifically described	Foreword, 1
2 The health question(s) covered by the guideline is (are) specifically described	Foreword, 1
3 The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described	Foreword, 1
<b>Stakeholder involvement</b>	
4 The guideline development group includes individuals from all the relevant professional groups	Foreword
5 The views and preferences of the target population (patients, public, etc.) have been sought	Foreword
6 The target users of the guideline are clearly defined	1
<b>Rigour of development</b>	
7 Systematic methods were used to search for evidence	Foreword
8 The criteria for selecting the evidence are clearly described	Foreword
9 The strengths and limitations of the body of evidence are clearly described	Foreword
10 The methods for formulating the recommendations are clearly described	Foreword
11 The health benefits, side effects and risks have been considered in formulating the recommendations	n/a
12 There is an explicit link between the recommendations and the supporting evidence	Throughout
13 The guideline has been externally reviewed by experts prior to its publication	Foreword
14 A procedure for updating the guideline is provided	Foreword
<b>Clarity of presentation</b>	
15 The recommendations are specific and unambiguous	Throughout
16 The different options for management of the condition or health issue are clearly presented	Foreword, 7, 8, 14
17 Key recommendations are easily identifiable	Throughout
<b>Applicability</b>	
18 The guideline describes facilitators and barriers to its application	Foreword
19 The guideline provides advice and/or tools on how the recommendations can be put into practice	Appendix A
20 The potential resource implications of applying the recommendations have been considered	Foreword
21 The guideline presents monitoring and/or auditing criteria	16
<b>Editorial independence</b>	
22 The views of the funding body have not influenced the content of the guideline	Foreword
23 Competing interest of guideline development group members have been recorded and addressed	Foreword